Go Pro
→ WATCH THIS BEFORE DECEMBER 8th!! (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Neuralstem, Inc. stock logo
CUR
Neuralstem
$1.87
-2.1%		$1.06
$1.10
▼
$13.78
$3.93M1.81236,278 shs1.84 million shs
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
$0.75
-3.3%		$0.96
$0.69
▼
$3.78
$15.25M1.01253,641 shs697,349 shs
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$1.99
+6.4%		$3.07
$2.90
▼
$23.42
$13.70M1.4116,506 shs204,235 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$3.30
$3.95
$1.11
▼
$17.50
$13.91M0.162,847 shs352 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Neuralstem, Inc. stock logo
CUR
Neuralstem
0.00%0.00%0.00%0.00%+108.19%
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
0.00%-1.12%+5.51%-63.07%-62.89%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
0.00%-1.97%-35.81%-53.61%-87.10%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00%+3.12%-22.72%-21.63%-76.28%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Neuralstem, Inc. stock logo
CUR
Neuralstem
$1.87
-2.1%		$1.06
$1.10
▼
$13.78
$3.93M1.81236,278 shs1.84 million shs
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
$0.75
-3.3%		$0.96
$0.69
▼
$3.78
$15.25M1.01253,641 shs697,349 shs
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$1.99
+6.4%		$3.07
$2.90
▼
$23.42
$13.70M1.4116,506 shs204,235 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$3.30
$3.95
$1.11
▼
$17.50
$13.91M0.162,847 shs352 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Neuralstem, Inc. stock logo
CUR
Neuralstem
0.00%0.00%0.00%0.00%+108.19%
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
0.00%-1.12%+5.51%-63.07%-62.89%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
0.00%-1.97%-35.81%-53.61%-87.10%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00%+3.12%-22.72%-21.63%-76.28%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Neuralstem, Inc. stock logo
CUR
Neuralstem
0.00
N/AN/AN/A
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
2.33
Hold$6.50766.67% Upside
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2.33
Hold$51.752,500.50% Upside
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CUR, DARE, ZIVO, and PSTV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/16/2026
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
9/14/2026
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$1.00
8/25/2026
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/17/2026
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/17/2026
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/17/2026
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Neuralstem, Inc. stock logo
CUR
Neuralstem
$260K15.10N/AN/A$6.64 per share0.28
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
$1.03M14.32N/AN/A$0.20 per share3.75
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/AN/AN/AN/A$0.72 per shareN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$15.85K877.57N/AN/A($0.81) per share-4.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Neuralstem, Inc. stock logo
CUR
Neuralstem
-$4.93MN/AN/AN/AN/A-39,417.64%-170.51%-110.16%N/A
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-$13.40M-$0.70N/AN/AN/A-803.80%-748.30%-38.75%11/12/2026 (Estimated)
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$22.39M-$2.30N/AN/AN/A-230.24%-198.48%-73.13%N/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
-$7.78M-$1.40N/AN/AN/AN/AN/A-2,240.92%12/2/2026 (Estimated)

Latest CUR, DARE, ZIVO, and PSTV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-$0.2967-$0.20+$0.0967-$0.20$0.00 million$0.19 million
8/13/2026Q2 2026
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$0.88-$1.31-$0.43-$1.31$1.11 million$0.41 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Neuralstem, Inc. stock logo
CUR
Neuralstem
N/AN/AN/AN/AN/A
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
N/AN/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/AN/AN/AN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Neuralstem, Inc. stock logo
CUR
Neuralstem
N/A
2.53
2.53
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
N/A
0.99
0.99
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/A
2.27
2.27
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/A
0.17
0.17

Institutional Ownership

CompanyInstitutional Ownership
Neuralstem, Inc. stock logo
CUR
Neuralstem
38.30%
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
6.70%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
3.28%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
12.83%

Insider Ownership

CompanyInsider Ownership
Neuralstem, Inc. stock logo
CUR
Neuralstem
5.38%
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
4.10%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2.50%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
48.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Neuralstem, Inc. stock logo
CUR
Neuralstem
62.10 millionN/ANot Optionable
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
2419.67 million18.86 millionNot Optionable
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
206.88 million6.71 millionNot Optionable
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
104.22 million2.91 millionNot Optionable

Recent News About These Companies

ZIVO Bioscience (NASDAQ:ZIVO) Stock Price Passes Below 200 Day Moving Average - Here's Why
September 19, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31032241
Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace
May 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260512411739/en/zivo-bioscience-inc.-announces-transition-to-otcid-marketplace/
Zivo Bioscience Inc. Wt
April 11, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/zivow
ZIVO Bioscience Provides Special Letter to Shareholders
March 27, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260327190358/en/ZIVO-Bioscience-Provides-Special-Letter-to-Shareholders/
Maxim Group Reaffirms Their Hold Rating on Zivo Bioscience (ZIVO)
December 15, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ZIVO/pressreleases/36474537/maxim-group-reaffirms-their-hold-rating-on-zivo-bioscience-zivo/
ZIVO Bioscience releases letter to shareholders
September 14, 2025  |  wattagnet.comW
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
September 10, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250910182550/en/zivo-bioscience-ceo-letter-to-shareholders-highlights-progress-with-human-nutrition-and-animal-therapeutic-businesses/
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry
June 20, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250620564330/en/zivo-bioscience-and-leading-global-animal-health-company-to-advance-zivo%e2%80%99s-immune-enhancing-compounds-in-poultry/
University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
May 7, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/university-delaware-study-identifies-optimal-215400486.html
University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
May 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250506414477/en/university-of-delaware-study-identifies-optimal-formulation-of-zivo%e2%80%99s-active-ingredients-for-further-testing-to-mitigate-avian-influenza-in-poultry/
ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry
February 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250206639313/en/zivo-bioscience-plans-new-study-with-university-of-delaware-to-combat-avian-influenza-in-poultry/
Zivo Bioscience issues new shares, raises $1.5 million
January 28, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/zivo-bioscience-issues-new-shares-raises-1-5-million/ar-AA1xZjTM
Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed
January 1, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/tuesdays-insider-activity-top-buys-and-sells-in-us-stocks-revealed-93CH-3793355
ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
December 20, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20241220941955/en/ZIVO-Bioscience-Reports-Preliminary-Efficacy-of-its-Proprietary-Active-Ingredients-in-the-Battle-Against-Avian-Influenza/
Regencell Bioscience Holdings Ltd RGC
February 1, 2024  |  morningstar.comM
ZIVO Bioscience Announces Uplisting to OTCQB Market
January 29, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/zivo-bioscience-announces-uplisting-otcqb-130000877.html?.tsrc=rss
Ideaya Biosciences
January 18, 2024  |  forbes.comhttps://www.forbes.com/companies/ideaya-biosciences/
Dare Bioscience Inc DARE
January 14, 2024  |  morningstar.comM
Zivo Bioscience Inc (ZIVO) USD0.001
November 11, 2023  |  hl.co.ukhttps://www.hl.co.uk/shares/shares-search-results/z/zivo-bioscience-inc-usd1.001/costs
Zivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72
November 1, 2023  |  msn.comhttps://www.msn.com/en-us/money/markets/zivo-bioscience-zivo-price-target-increased-by-50000-to-3672/ar-AA1jflXo

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Autonomous military drone with AV-style logo on the nose sitting on a runway, representing AeroVironment and the defense drone industry.
AeroVironment's Record Backlog and Earnings Beat Fuel Recovery Case
By Thomas Hughes | September 10, 2026
Illustration of a computer chip on a circuit board with an upward green stock chart line in a server room.
Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
By Thomas Hughes | August 31, 2026
Adobe logo displayed on a wall behind an office desk with a laptop, notebook, and pens.
Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
By Dan Schmidt | September 14, 2026
Foldable Apple smartphone displayed on a table with a lit Apple logo and city skyline in the background.
Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
By Sam Quirke | August 30, 2026
Oil refinery complex with storage tanks, distillation towers, and piping, photographed at dusk with a chain-link fence in foreground.
Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
By Chris Markoch | September 12, 2026
Neuralstem stock logo

Neuralstem NASDAQ:CUR

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Dare Bioscience stock logo

Dare Bioscience NASDAQ:DARE

$0.75 -0.03 (-3.29%)
Closing price 04:00 PM Eastern
Extended Trading
$0.74 -0.01 (-1.87%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Plus Therapeutics stock logo

Plus Therapeutics NASDAQ:PSTV

$1.99 +0.12 (+6.42%)
As of 09/25/2026

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

ZIVO Bioscience stock logo

ZIVO Bioscience NASDAQ:ZIVO

$3.30 0.00 (0.00%)
As of 09/25/2026 03:08 PM Eastern

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas